Disclaimer: This article has been developed and funded by Daiichi Sankyo ... in breast and lung cancer, two of the most common cancers and biggest killers in our society. Precision medicines ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer.

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan ... in the press release. According to the American Cancer Society, breast cancer is the most common cancer in ...

Daiichi Sankyo (OTCPK:DSKYF ... as a late-line option for certain cases of breast cancer. Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP ...

The FY2024 revenue forecast remains unchanged, despite delays in approvals for Datroway in the lung cancer field ... offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

2 Currently, there are no TA-MUC1 directed therapies approved for any type of cancer ... Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of ...

About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that ... for people with cancer, cardiovascular and other ...

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of ...